Scientific publications

A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.

Project Indication

Easyhaler® salmeterol-fluticasone

Asthma, COPD


 

Scientific articles

Jõgi et al; J Aerosol Med Pulm Drug Deliv

 

 

9 October 2018

 

 

In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial. Open access.

 

Darolutamide

Prostate cancer (nmCRPC)

Scientific articles

Fizazi et al; Expert Rev Anticancer Ther

 

26 August 2015

 

ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Open access

Darolutamide

Prostate cancer (mHSPC)

Scientific articles

Massard et al; Eur Urology

 

17 October 2015

 

Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Open access

ODM-109 (oral levosimendan)

ALS

Congress posters

NEALS 2018

 

ALS / MND 2017

 


ALS / MND 2017

 

2-4 October 2018

 

8-10 December 2017

 


8-10 December 2017

 

Oral levosimendan in ALS: the REFALS phase 3 study design

 

Scientific background for developing oral levosimendan (ODM-109) for the treatment of Amyotrophic Lateral Sclerosis

Oral levosimendan (ODM-109): Key placebo-controlled results from the phase 2 study in ALS patients with SVC between 60-90% predicted at screening

ODM-203

(targeted FGFR+VEGFR inhibitor)

Solid tumours

Congress posters

ESMO 2018

 

 

Cholangiocarcinoma Foundation Annual

Conference 2017

 
ESMO 2016

 


ASCO 2016

 

 

Scientific articles

Holmström et al; Mol Can Ther 

 

19-23 October 2018

 

 

1-3 February 2017



7-11 October 2016

 


3-7 June 2016

 

 

 

9 October 2018
 

 

Phase 1/2 study of ODM-203, e selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors 

 

Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

Dose escalation study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumors

 

 

ODM-203 a selective inhibitor of FGFR and VEGFR, shows strong anti-tumor activity, and induces anti-tumor immunity. Open access 

ODM-207 (BET protein inhibitor)

Cancer

  
   

Congress posters

ESMO 2018

 

 

AACR Annual Meeting 2018

 


2nd European Cancer Epigenetics

Conference 

 

AACR Annual Meeting 2017
 

 

19-23 October 2018

 

 

14-18 April 2018

 


11-13 May 2017

 

 

1-5 April 2017

 

ODM-207 - a novel BET bromodomain inhibitor with antitumor activity in nonclinical models of ER+ breast cancer

 

Therapeutic targeting of estrogen receptor positive breast cancer with the BETbromodomain inhibitor ODM-207 

 

Targeting cancer with a novel BET bromodomain inhibitor

 

 

Targeting cancer with a novel BET bromodomain inhibitor

 

Immune-mediated anti-tumor activity with a clinical stage BET bromodomain inhibitor ODM-207 in pre-clinical models

ODM-208 (CYP11A1 inhibitor)

Prostate cancer (CRPC)

     

Congress posters

ESMO 2018

 


ASCO GU 2018

 

 

The 24th Annual PCF Scientific Retreat Washington DC, USA

ESMO 2017

 

 

19-23 October 2018

 


8-10 February 2018

 

 

5-7 October 2017

 

8-12 September 2017

 

CYP11A1 inhibitor as a therapeutic approach for the treatment of castration resistant prostate cancer

 

CYP11A1 inhibitor as a threapeutic approach for the treatment of castration resistant prostate cancer

 

ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer

ODM-208, a novel CYP11A1-inhibitor as a therapeutic approach for the treatment of castration-resistant prostate cancer